StockDecksAstraZeneca vs GSK
AstraZeneca PLC (AZN.L) and GSK plc (GSK.L) · Healthcare
As of 24 October 2026, AstraZeneca has a StockDecks Fundamental Score of +19 (grade B) and GSK +4 (grade B−), on a −100 to +100 scale. AstraZeneca rates higher on Financial Health and Growth; GSK rates higher on Profitability and Valuation.
| Rating | AZN.L | GSK.L |
|---|---|---|
| Fundamental Score | +19Grade B | +4Grade B− |
| Financial Health | -1 | -11 |
| Profitability | +64 | +65 |
| Growth | -3 | -64 |
| Valuation | +17 | +26 |
Both companies are measured against the same Healthcare benchmarks, so their scores compare directly. Scores describe each company as it stands; they are not forecasts or recommendations.
The measures side by side
Each figure is the latest reported value; the number beneath is how it scores on the −100 to +100 scale. A dash means no genuine figure is available. Tap a measure’s name for a plain-English explanation.
Financial Health
| Measure | AZN.L | GSK.L |
|---|---|---|
| Debt to equity | 0.64×+32 | 1.06×-3 |
| Current ratio | 0.89×-21 | 0.82×-33 |
| Quick ratio | 0.66×-24 | 0.52×-51 |
| FCF / Total debt | 0.16×+2 | 0.19×+10 |
Profitability
| Measure | AZN.L | GSK.L |
|---|---|---|
| Gross margin | 81.7%+93 | 73.5%+91 |
| Operating margin | 23.5%+59 | 30.9%+91 |
| Net margin | 17%+63 | 14.5%+41 |
| Return on equity | 22%+91 | 33.4%+96 |
| Gross profit / assets | 42.2%+44 | 38.7%+37 |
| Asset turnover | 0.51× | 0.53× |
Growth
| Measure | AZN.L | GSK.L |
|---|---|---|
| Revenue growth (YoY) | 6.4%+10 | 5.3%+2 |
| Earnings growth (YoY) | 2.5%-9 | -69.5%-97 |
| Earnings growth (Q) | 2.3%-10 | -69.9%-97 |
Valuation
| Measure | AZN.L | GSK.L |
|---|---|---|
| P/E (trailing) | 26.55×-4 | 16.05×+81 |
| PEG ratio | 1.23×+35 | 6.17×-98 |
| Price/Sales | 3.24×+53 | 2.29×+81 |
| EV/EBITDA | 11.18×+49 | 8.38×+85 |
| FCF yield | 2.6%-32 | 4.6%+9 |
| Forward P/E | — | 9.97×+92 |
| Price/Book | — | 4.3×-23 |
Key figures
| AZN.L | GSK.L | |
|---|---|---|
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Market cap | £198.9B | £75.9B |
| Dividend yield | 1.86% | 3.59% |
| Payout ratio | 46.95% | 56.64% |
| Beta | 0.21 | 0.28 |
About the companies
AstraZeneca. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Full AstraZeneca rating
GSK. GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. Full GSK rating
See the live cards
These figures were captured on 24 October 2026. StockDecks shows the current numbers, plus Hype, Analyst Upside, Trend Signals and Insider Track, all free.